Stay updated on Mirvetuximab Combo in FRα+ Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Mirvetuximab Combo in FRα+ Ovarian Cancer Clinical Trial page.

Latest updates to the Mirvetuximab Combo in FRα+ Ovarian Cancer Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoNo Change Detected
- Check17 days agoChange DetectedThe page now displays Revision: v3.5.0, replacing the previous Revision: v3.4.3.SummaryDifference0.0%

- Check24 days agoNo Change Detected
- Check31 days agoChange DetectedRevision history updated to add v3.4.3 and remove v3.4.2.SummaryDifference0.0%

- Check52 days agoChange DetectedFallopian tube cancer added to the study keywords; the record revision updated from v3.4.1 to v3.4.2.SummaryDifference0.1%

- Check60 days agoChange DetectedAdded Primary peritoneal carcinoma to the terminology and updated the page revision from v3.4.0 to v3.4.1.SummaryDifference0.1%

- Check82 days agoChange DetectedAdded Revision: v3.3.4 and removed Revision: v3.3.3 on the page header.SummaryDifference0.0%

- Check110 days agoChange DetectedLocations were consolidated into one Locations section with individual state subsections (California, Massachusetts, Nevada, Ohio, Oklahoma, Pennsylvania). This update is part of revision v3.3.3.SummaryDifference0.6%

Stay in the know with updates to Mirvetuximab Combo in FRα+ Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Mirvetuximab Combo in FRα+ Ovarian Cancer Clinical Trial page.